Iram Fatima

About

Dr. Fatima is a research instructor with 10+ years of hands-on experience conducting experiments in cancer biology, endometrial cancer, breast cancer and biotechnology including a recent leadership role at one of the world’s leading research universities. She completed her PhD in Biotechnology from Jamia Hamdard University, India. After completing her PhD, she worked as a Post-Doctoral Fellow at All India Institutes of Medical Science (AIIMS) in New Delhi, India for one year.Later on she joined University of Tennessee Health Science Center (UTHSC) as a Postdoctoral Research Fellow in Memphis, Tennessee, USA and presently she is working as a Research Instructor in the Department of Biochemistry and Molecular Biology at the University of Nebraska Medical Center, Omaha, Nebraska, USA.

Moreover, she has published over 18 peer-reviewed articles and numerous abstracts, as well as two book chapters. Dr. Fatima also serves as Reviewer and Editorial Boarder Member for more than 10 peer-reviewed journals.

Employment

• University of Nebraska Medical Center Research Instructor
  2019 - Present
• University of Nebraska Medical Center Postdoc Research Associate
  2018 - 2019
• University of Tennessee Health Science Center Postdoctoral Research Fellow
  2014 - 2018
• All India Institute of Medical Sciences Research Associate
  2013 - 2014
• Central Drug Research Institute Senior Research Fellow
  2010 - 2013
• Central Drug Research Institute Junior Research Fellow
  2008 - 2010

Education

• Jamia Hamdard Doctor of Philosophy in Biotechnology
  2009 - 2014
• University of Lucknow Master of Science in Biotechnology
  2005 - 2007
• Mahatma Jyotiba Phule Rohilkhand University Bachelor of Science in Biotechnology
  2002 - 2005

Projects & Funding

Projects & funding information is unavailable.

Publications (20)

• MASTL: A novel therapeutic target for Cancer Malignancy
  Cancer Medicine 2020 DOI: 10.1002/cam4.3141
  +Save
• Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling
  Cancers 2019 DOI: 10.3390/cancers11122039
  +Save
• Abstract 2541: Mastl regulates EGFR signaling to promote pancreatic cancer progression
  Molecular and Cellular Biology / Genetics 2019 DOI: 10.1158/1538-7445.am2019-2541
  +Save
• Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.
  Cancer research 2018 DOI: 10.1158/0008-5472.can-18-1255
  +Save
• The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
  Cancer research 2018 DOI: 10.1158/0008-5472.can-18-1069
  +Save
• Abstract 1233: WNT inhibitor ICG-001 prevents visceral metastatic triple negative breast cancer in a chemo-resistant patient derived xenograft -PDX-model
  Experimental and Molecular Therapeutics 2017 DOI: 10.1158/1538-7445.am2017-1233
  +Save
• The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer
  PLoS ONE 2017 DOI: 10.1371/journal.pone.0189864
  +Save
• Recent Advances in Molecularly Targeted Therapies for Endometrial Cancer and their Future Clinical Implications
  2015
  +Save
• (+)-Dehydroabietylamine derivatives target triple-negative breast cancer
  European Journal of Medicinal Chemistry 2015 DOI: 10.1016/j.ejmech.2015.07.034
  +Save
• Inhibitory effect of 2-(piperidinoethoxyphenyl)-3-(4-hydroxyphenyl)-2H- benzo(b)pyran (K-1) on human primary endometrial hyperplasial cells mediated via combined suppression of Wnt/β-catenin signaling and PI3K/Akt survival pathway
  Cell Death and Disease 2014 DOI: 10.1038/cddis.2014.334
  +Save